Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx completes funding, raises €50 million

This article was originally published in Scrip

Executive Summary

Belgian antibody firm Ablynx has completed its secondary public offering, raising €50 million through the sale of just under 6.7 million new shares at €7.50 each. An over-allotment option of up to 400,000 shares worth €3 million in total will be covered by lending shareholders selling existing shares. The company said that the base offering at the final offer price was subscribed by about 1.1 times. The transaction leaves Ablynx with a market capitalisation of around €327 million based on the final offer price. The new shares are expected to begin trading on Euronext Brussels on March 18th. Ablynx announced its offering last week, when it set the offer price range at €7.20-7.75 (scripnews.com, March 8th, 2010).

You may also be interested in...



What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient

From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007312

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel